Organon (OGN) Return on Capital Employed (2021 - 2026)
Organon (OGN) posted quarterly Return on Capital Employed of 10.75% for Q2 2026, down 123.0% year-over-year from 46.75% in Q2 2025, and little changed on a QoQ basis from 10.8% in Q1 2026.
Organon (OGN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Organon has reported Return on Capital Employed for 6 years, with the latest figure at 10.75% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 10.75%, down 123.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 10.75% (down 123.0% YoY), and the FY2025 annual result was 10.68%, down 408.0% from the prior year.
- Return on Capital Employed was little changed at 10.75% in Q2 2026, from 10.8% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 12.59% in Q1 2025 and troughed at 21.38% in Q4 2023.
- A 5-year average of 4.79% and a median of 11.2% in 2022 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2022, when Return on Capital Employed plunged 1308 bps; it then soared 3302 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 14.32% in 2022, then plunged by 49 bps to 21.38% in 2023, then jumped by 130 bps to 6.43% in 2024, then surged by 63 bps to 10.45% in 2025, then rose by 3 bps to 10.75% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 10.75% in Q2 2026, 10.8% in Q1 2026, and 10.45% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 10.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.75% |
| Mar 31, 2026 | 10.80% |
| Dec 31, 2025 | 10.45% |
| Sep 30, 2025 | 11.15% |
| Jun 30, 2025 | 11.98% |
| Mar 31, 2025 | 12.59% |
| Dec 31, 2024 | 6.43% |
| Sep 30, 2024 | -2.18% |
| Jun 30, 2024 | -12.45% |
| Mar 31, 2024 | -20.43% |
| Dec 31, 2023 | -21.38% |
| Sep 30, 2023 | -20.53% |
| Jun 30, 2023 | -17.48% |
| Mar 31, 2023 | -16.42% |
| Dec 31, 2022 | -14.32% |
| Sep 30, 2022 | -12.83% |
| Jun 30, 2022 | -12.22% |
| Mar 31, 2022 | -10.18% |
| Dec 31, 2021 | -10.14% |
| Sep 30, 2021 | -6.89% |